Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cell-based immunotherapy in liver transplantation to minimize systemic immunosuppression
2024-514866-37-01Phase 2Authorised
- Sponsor
- Karolinska University Hospital
- Start
- Nov 2024
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donor-specific immunomodulatory cells in hepatic disease, sponsored by Karolinska University Hospital. Primary endpoint: Safety evaluation at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
donor-specific immunomodulatory cells
03
Conditions
hepatic disease
Beyond the preview
Go deeper on 2024-514866-37-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514866-37-01.